About

In a bold leap forward for women’s healthcare, Mestrualia, a pioneering health-tech company, today unveiled the launch of its AI-powered medical protocol designed specifically to transform the way chronic pelvic pain (CPP) is diagnosed and treated. Affecting 1 in 5 women globally, CPP has remained one of the most misunderstood, misdiagnosed, and often outright dismissed conditions in modern medicine. With its innovative approach—merging early detection, clinical intelligence, and personalized care pathways—Mestrualia aims to reduce diagnostic timelines by up to 80%, dramatically alleviating patient suffering while easing long-term healthcare costs.

At the heart of Mestrualia’s mission lies a personal story of pain, resilience, and determination. Franziska Roessler, Mestrualia’s founder and CEO, knows firsthand the devastation that CPP can cause—not just physically, but emotionally, mentally, and financially. For years, Roessler navigated a fractured healthcare system in search of answers to a pain no one seemed to understand. Doctors dismissed her symptoms as psychosomatic, irrelevant, or "just part of being a woman." Appointments ended with prescriptions that masked symptoms but failed to address root causes. In total, she spent years in diagnostic limbo—enduring misdiagnoses, unnecessary interventions, and a growing sense of hopelessness.

“I founded Mestrualia because I lived it,” Roessler shares. “The silence, the misdiagnoses, the emotional and financial toll—this is what drives me to build a smarter, faster, and more compassionate solution. Our goal is to ensure that no woman is ever again left to suffer in silence or wait seven years for a proper diagnosis.”

That seven-year figure is not an exaggeration—it’s the average time it takes for a woman with CPP to receive a correct diagnosis, a statistic that underscores the massive systemic failure in women’s health. Despite the growing public discourse around endometriosis, adenomyosis, interstitial cystitis, and other sources of CPP, diagnostic inertia remains the norm. Physicians are often undertrained in identifying these complex conditions, and clinical protocols lag far behind the lived experiences of millions.

Mestrualia’s AI-driven platform challenges this status quo by leveraging machine learning algorithms trained on thousands of clinical data points—patient histories, symptoms, test results, and imaging data—to identify patterns and generate high-probability diagnoses earlier in the care journey. But the innovation doesn’t stop at detection. The system also recommends individualized treatment plans, connecting patients to vetted specialists and therapeutic options tailored to their specific condition, medical history, and lifestyle.

What makes Mestrualia’s protocol revolutionary is not just the technology—but its fundamentally patient-centered approach. Where traditional medicine often views CPP as a puzzle to be solved, Mestrualia treats it as a human experience to be understood, integrating physical, emotional, and psychological support into the care framework. The company has also launched a patient-facing app to streamline access to diagnostics, facilitate symptom tracking, and provide community support for those navigating long-term pelvic pain.

For Roessler, this isn’t simply a business—it’s a movement. It’s about rewriting the narrative of pain that generations of women have been told to normalize or ignore. “There’s a silent epidemic of women being told their pain is imaginary, hormonal, or ‘just stress,’” she says. “It’s not. It’s real, and it’s time we start treating it with the seriousness it deserves.”

Backed by a multidisciplinary team of gynecologists, pain specialists, AI engineers, and patient advocates, Mestrualia is already gaining traction across Europe, with pilot programs set to roll out in select clinics in Germany, Austria, and the UK. Preliminary results from early trials are promising, showing a significant reduction in diagnostic delays, higher patient satisfaction, and more efficient treatment outcomes.

As awareness around women’s health finally begins to enter mainstream medical and policy conversations, Mestrualia stands at the vanguard of a new era—one in which female pain is not dismissed, but decoded; not silenced, but scientifically addressed.

In a world where pain has too often been gendered and invalidated, Mestrualia offers not just technology—but hope, justice, and a long-overdue commitment to equity in care.